Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jul 3, 2015

(R) Cantargia and Glycotope Biotechnology signs production agreement for lead product candidate CAN04

Jun 26, 2015

(R) Cantargia licenses BioWa POTELLIGENT® Technology platform for production of lead product candidate

May 28, 2015

(R) Cantargia obtains “Intention to Grant” notice from the European Patent Office

May 19, 2015

(R) Cantargia Interim Report for the period 1 Jan 2015 – 31 Mar 2015 available

Apr 20, 2015

(R) Cantargia strengthens management with a Vice President Clinical Development

Mar 17, 2015

(R) First day of trading in Cantargia shares and option rights on Nasdaq First North Stockholm

Mar 16, 2015

(R) Share transaction in Cantargia AB

Mar 11, 2015

(R) Nasdaq OMX approves Cantargia for listing on First North Stockholm

Feb 17, 2015

(R) Cantargia share offering prior to planned listing on Nasdaq First North in Stockholm oversubscribed

Jan 16, 2015

(R) Cantargia performs IPO ahead of planned listing on Nasdaq First North in Stockholm

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye